Health Condition 1: - Health Condition 2: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx
Conditions
Interventions
Intervention1: Nil: NIL
Intervention2: Nil: Nil
Sponsors
Nucgnex Lifesciences
Eligibility
Inclusion criteria
Inclusion criteria: Adult patient (18 Years) diagnosed with head and neck squamous cell cancer of oral cavity. understanding radiotherapy/Chemotherapy No prior mucositis at baseline Willing to take falxseed oil supplementation as part of their diet. able to provide informed concent
Exclusion criteria
Exclusion criteria: Patients with pre-existing mucositis before starting treatment Allergy to flaxseed or omega-3 supplements Severe gastrointestinal disorders Patients already using other omega-3 or mucositis-preventive supplements
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of mucositis (graded using the WHO Oral Toxicity Scale or CTCAE criteria).7 Severity of mucositis (assessed weekly). Mapping of mucositis by treating onco-physician Timepoint: Baseline, Weekly visit | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary Outcome Measures Pain score (Visual Analog Scale [VAS]) Dysphagia (difficulty swallowing) assessment Nutritional status (weight, BMI changes, dietary intake, Subjective Global Assessment) Quality of life (assessed via questionnaires, EORTC QOL-C30 & EORTC HN35 ) Adverse effects of flaxseed oil (e.g., gastrointestinal symptoms, allergic reactions). Timepoint: Week 4, week 8 | — |
Countries
India
Contacts
Public ContactDr Utpal Gaikwad
Krupamayi Hospital
Outcome results
None listed